EA202190799A1 - Макромолекулярные пролекарства на полимерной основе - Google Patents
Макромолекулярные пролекарства на полимерной основеInfo
- Publication number
- EA202190799A1 EA202190799A1 EA202190799A EA202190799A EA202190799A1 EA 202190799 A1 EA202190799 A1 EA 202190799A1 EA 202190799 A EA202190799 A EA 202190799A EA 202190799 A EA202190799 A EA 202190799A EA 202190799 A1 EA202190799 A1 EA 202190799A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- prolectives
- polymer
- based macromolecular
- macromolecular
- macromolecular prodrugs
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732199P | 2018-09-17 | 2018-09-17 | |
| PCT/US2019/051457 WO2020061007A1 (en) | 2018-09-17 | 2019-09-17 | Polymer-based macromolecular prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190799A1 true EA202190799A1 (ru) | 2021-06-22 |
Family
ID=69887739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190799A EA202190799A1 (ru) | 2018-09-17 | 2019-09-17 | Макромолекулярные пролекарства на полимерной основе |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11253603B2 (enExample) |
| EP (1) | EP3852793B1 (enExample) |
| JP (1) | JP7546552B2 (enExample) |
| KR (1) | KR20210072002A (enExample) |
| CN (2) | CN112996533B (enExample) |
| AU (1) | AU2019344783B2 (enExample) |
| CA (1) | CA3112778A1 (enExample) |
| EA (1) | EA202190799A1 (enExample) |
| MX (1) | MX2021003116A (enExample) |
| WO (1) | WO2020061007A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112996533B (zh) * | 2018-09-17 | 2025-01-10 | 费城儿童医院 | 基于聚合物的大分子前药 |
| CN115443947B (zh) * | 2022-10-12 | 2023-11-21 | 江苏省人民医院（南京医科大学第一附属医院） | 高血压动物模型的制备方法 |
| WO2025101904A1 (en) * | 2023-11-08 | 2025-05-15 | The Children's Hospital Of Philadelphia | Norepinephrine transporter-targeted prodrugs for cancer therapy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999052861A1 (de) * | 1998-04-09 | 1999-10-21 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Neue benzylguanidinderivate für die therapie, in-vivo- und in-vitro-diagnostik |
| JP2002255821A (ja) * | 2001-03-06 | 2002-09-11 | Yakult Honsha Co Ltd | 抗癌剤耐性癌に対する治療剤 |
| US7591994B2 (en) * | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US20040258754A1 (en) * | 2003-06-18 | 2004-12-23 | Valery Alakhov | Compositions for oral administration of camptothecin and its analogs |
| KR101200729B1 (ko) | 2003-09-17 | 2012-11-13 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| CA2543722C (en) * | 2003-10-29 | 2011-01-04 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| WO2007106549A2 (en) * | 2006-03-15 | 2007-09-20 | Alza Corporation | Method for treating brain cancer |
| CA2662973A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Lysine-based polymeric linkers |
| US20090074074A1 (en) | 2007-06-29 | 2009-03-19 | The Hong Kong University Of Science And Technology | Multiple description encoder and decoder for transmitting multiple descriptions |
| CN102159250B (zh) * | 2008-08-11 | 2014-08-06 | 尼克塔治疗公司 | 多臂的聚合烷酸酯偶联物 |
| PT2349346T (pt) | 2008-09-23 | 2019-10-24 | Nektar Therapeutics | Método de dosagem metronómica com profármacos de camptotecina (e.g. peg-irinotecano). |
| CN102215688A (zh) * | 2008-10-21 | 2011-10-12 | 安龙制药公司 | 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗 |
| CN101385860B (zh) * | 2008-10-31 | 2011-11-02 | 美国草药泉有限责任公司 | 喜树碱及其衍生物的非线性聚乙二醇前药 |
| EP2456464A4 (en) | 2009-07-22 | 2013-02-20 | Enzon Pharmaceuticals Inc | METHODS OF TREATING POSITIVE HER2 CANCER WITH HER2 RECEPTOR ANTAGONIST IN COMBINATION WITH 7-ETHYL-10-HYDROXYCAMPTOTHECIN MULTI-ARM POLYMERIC CONJUGATES |
| HUE043689T2 (hu) | 2009-11-18 | 2019-09-30 | Nektar Therapeutics | Polimer-gyógyszer savas sói |
| WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
| CN102626518B (zh) * | 2012-05-09 | 2014-05-28 | 中国药科大学 | 一种包载难溶性药物的泊洛沙姆/两亲性多糖混合胶束的制备和应用 |
| CN104813167B (zh) | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| WO2014194289A1 (en) | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| US10016411B2 (en) * | 2013-10-04 | 2018-07-10 | Prolynx Llc | Slow-release conjugates of SN-38 |
| WO2015191583A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016050210A1 (zh) | 2014-10-01 | 2016-04-07 | 厦门赛诺邦格生物科技有限公司 | 一种多官能化聚乙二醇衍生物及其制备方法 |
| CN104877127B (zh) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| WO2018048859A1 (en) | 2016-09-06 | 2018-03-15 | Cerebral Therapeutics | Direct brain administration of chemotherapeutics to the csf for patients with primary and secondary brain tumors |
| AU2018255458B2 (en) | 2017-04-21 | 2020-06-25 | Brightgene Bio-Medical Technology Co., Ltd. | Multi-arm targeted anti-cancer conjugate |
| CN111328330B (zh) | 2017-09-08 | 2024-03-08 | 普罗蒙托里治疗有限公司 | 作为免疫调节剂的磷铂化合物及其治疗用途 |
| WO2019090141A1 (en) | 2017-11-02 | 2019-05-09 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
| US20190375732A1 (en) | 2018-05-14 | 2019-12-12 | David Hung | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN112996533B (zh) * | 2018-09-17 | 2025-01-10 | 费城儿童医院 | 基于聚合物的大分子前药 |
| CN111603567B (zh) | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| KR20220008869A (ko) | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
-
2019
- 2019-09-17 CN CN201980060783.3A patent/CN112996533B/zh active Active
- 2019-09-17 WO PCT/US2019/051457 patent/WO2020061007A1/en not_active Ceased
- 2019-09-17 MX MX2021003116A patent/MX2021003116A/es unknown
- 2019-09-17 EP EP19863240.8A patent/EP3852793B1/en active Active
- 2019-09-17 JP JP2021514531A patent/JP7546552B2/ja active Active
- 2019-09-17 AU AU2019344783A patent/AU2019344783B2/en active Active
- 2019-09-17 CA CA3112778A patent/CA3112778A1/en active Pending
- 2019-09-17 CN CN202510008384.XA patent/CN119950749A/zh active Pending
- 2019-09-17 KR KR1020217011264A patent/KR20210072002A/ko active Pending
- 2019-09-17 US US16/969,790 patent/US11253603B2/en active Active
- 2019-09-17 EA EA202190799A patent/EA202190799A1/ru unknown
-
2022
- 2022-02-11 US US17/670,218 patent/US11642414B2/en active Active
-
2023
- 2023-04-27 US US18/140,289 patent/US12311028B2/en active Active
-
2025
- 2025-05-13 US US19/206,574 patent/US20250387496A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020061007A1 (en) | 2020-03-26 |
| MX2021003116A (es) | 2021-05-14 |
| CA3112778A1 (en) | 2020-03-26 |
| KR20210072002A (ko) | 2021-06-16 |
| US11253603B2 (en) | 2022-02-22 |
| CN119950749A (zh) | 2025-05-09 |
| US20210000967A1 (en) | 2021-01-07 |
| US12311028B2 (en) | 2025-05-27 |
| US20250387496A1 (en) | 2025-12-25 |
| US20220160886A1 (en) | 2022-05-26 |
| JP2022501341A (ja) | 2022-01-06 |
| AU2019344783A1 (en) | 2021-04-08 |
| AU2019344783B2 (en) | 2025-10-23 |
| US11642414B2 (en) | 2023-05-09 |
| EP3852793A1 (en) | 2021-07-28 |
| NZ773863A (en) | 2024-10-25 |
| JP7546552B2 (ja) | 2024-09-06 |
| EP3852793B1 (en) | 2025-11-19 |
| CN112996533A (zh) | 2021-06-18 |
| CN112996533B (zh) | 2025-01-10 |
| US20230414766A1 (en) | 2023-12-28 |
| EP3852793A4 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
| CY1123983T1 (el) | Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου | |
| CY1123788T1 (el) | Αντισωματα αντι-ακτιβινης α και χρησεις αυτων | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1123441T1 (el) | Μορια με ειδικοτητα στα cd45 και cd79 | |
| CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| EA201992780A1 (ru) | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания | |
| EA201690744A1 (ru) | Конъюгаты белок-полимер-лекарственное средство | |
| CY1122956T1 (el) | Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων | |
| CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
| EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
| CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
| PH12019502333A1 (en) | Targeted compositions | |
| CY1121870T1 (el) | Anti-egfrviii αντισωματα και χρησεις αυτων | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| MX2023001582A (es) | Conjugados proteina-polimero-farmaco. | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| CY1121710T1 (el) | Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας | |
| MX2023002599A (es) | Conjugados de compuestos de tubulisina cuaternizada. | |
| EA201291194A1 (ru) | Индолы | |
| NZ730563A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| CY1124704T1 (el) | Παραγωγα sobetirome | |
| MX385823B (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
| EA201692425A1 (ru) | Модифицированные биополимеры и способы их получения и использования | |
| MX2018008321A (es) | Tratamiento de tumores ocasionados por disfuncion metabolica. |